Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Trial ID # NCT03029598
Phase I/II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial Carboplatin, Pembrolizumab
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

27; median 5 prior therapies (2-9)

Therapy Setting

Recurrence

Study Design

Open-Label, Non-randomized

Endpoints

ORR, DCR, PFS, OS, evaluated per RECIST

Biomarkers

Exploratory: PD-L1 status

Efficacy

ORR: 10.6% (3PR, n=29)
DCR: 62% (3PR, 15SD, n=29)
PFS: 4.6 months
OS: 11.3 months

7 of 23 evaluable patients (30.4%) had archival tumor with modified percent scoring ≥5 for PD-L1 and all achieved PR (3/7, 42.8%) or SD (4/7, 57.2%)

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE:

Conclusion

Promising activity of pembrolizumab with low dose carboplatin in heavily pretreated patients

Reference

Liao JB et al. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. J Immunother Cancer (2021)
https://pubmed.ncbi.nlm.nih.gov/34531249/

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.